<DOC>
	<DOCNO>NCT00193063</DOCNO>
	<brief_summary>Due remarkable activity salvage treatment woman metastatic breast cancer well additive activity observe gemcitabine administer combination trastuzumab , clinical activity combination gemcitabine administer trastuzumab represent excite ideal combination evaluate Her 2 over-expressing metastatic breast cancer patient .</brief_summary>
	<brief_title>Weekly Gemcitabine Trastuzumab Treatment Patients With Human Epidermal Growth Factor Receptor 2 ( HER2 ) Positive Metastatic Breast Cancer</brief_title>
	<detailed_description>Upon determination eligibility , patient receive : Gemcitabine + Trastuzumab</detailed_description>
	<mesh_term>Breast Neoplasms</mesh_term>
	<mesh_term>Gemcitabine</mesh_term>
	<mesh_term>Trastuzumab</mesh_term>
	<criteria>To include study , must meet following criterion : Her2 positive metastatic breast cancer confirm biopsy Measurable disease Able perform activity daily live without considerable No previous chemotherapy gemcitabine No one prior chemotherapy regimen metastatic breast cancer Adequate bone marrow , liver renal function Normal heart function Give write informed consent prior enter study . You participate study follow apply : Received previous treatment gemcitabine History brain metastasis Serious underlie medical condition Please note : There additional inclusion/exclusion criterion . The study center determine meet criterion . If qualify trial , study personnel explain reason . If qualify , study personnel explain trial detail answer question may .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>February 2014</verification_date>
</DOC>